Biocardia announces late breaking clinical trial presentation on cardiamp heart failure trial at the american college of cardiology 2025 scientific sessions

Sunnyvale, calif., jan. 27, 2025 (globe newswire) -- biocardia, inc. [nasdaq: bcda] today announced that the results of its double-blind randomized placebo-controlled cardiamp hf phase 3 study have been accepted for presentation in a late-breaking symposium at the american college of cardiology 2025 scientific sessions, taking place in chicago, march 29-31, 2025.
BCDA Ratings Summary
BCDA Quant Ranking